RxDoctor Payments Data

Barry Tarpley, MD

Internal Medicine · Evans, GANPI 1659474534

Payments from drug & device makers

$9,164in general payments, 2019–2025

Across 623 payments — averaging $14.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • AstraZeneca$848
  • Amgen$743
  • Amarin Pharma, Inc.$485
  • Lilly USA, LLC$440
  • plus $4K from 40 others

What the payments were for

  • Food & beverage$9,10099%
  • Education$651%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,164 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$164,268
Medicare patients
680
Services billed
14,174

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide177$231,317
EliquisApixaban216$193,078
OzempicSemaglutide118$156,656
JardianceEmpagliflozin141$138,606
TrulicityDulaglutide54$69,546
JanuviaSitagliptin Phosphate76$60,097
FarxigaDapagliflozin Propanediol65$59,206
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$55,354
MyrbetriqMirabegron58$42,332
XareltoRivaroxaban42$38,964
RybelsusSemaglutide19$38,030
LinzessLinaclotide35$30,528
Bydureon BciseExenatide Microspheres19$29,469
Tresiba Flextouch U-100Insulin Degludec46$28,463
TradjentaLinagliptin25$12,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$440$300,864231 claims
Novo NordiskOzempic, Rybelsus$1,569$194,686137 claims
PfizerEliquis$177$193,078216 claims
Boehringer IngelheimJardiance, Tradjenta$411$151,392166 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$412$72,36297 claims
MerckJanuvia$187$60,09776 claims
AstraZenecaFarxiga$848$59,20665 claims
AbbVieLinzess, Synthroid, Fetzima$1,014$44,114134 claims
Astellas Pharma US IncMyrbetriq$178$42,33258 claims
Johnson & JohnsonXarelto$212$38,96442 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$7,312800 claims
Sanofi-aventis U.S. LLCLantus$110$4,94619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Evans

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →